Zhejiang Yizeda Pharmaceutical Technology

Zhejiang Yizeda Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, including non-alcoholic steatohepatitis (NASH), gout, and diabetes, as well as oncology and inflammatory conditions. Its lead candidate, YZD-0315, is a highly selective thyroid hormone receptor beta (THR-β) agonist currently being evaluated in Phase 2 clinical trials for the treatment of NASH. Yizeda leverages its internal R&D capabilities to advance a pipeline of candidates aimed at addressing significant unmet medical needs in the global healthcare market. The company has successfully secured venture capital funding from prominent investors to support its clinical programs and expansion.